( non-motor secondary endpoints in thes...)Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa,Health

non-motor secondary endpoints in the study publication that were statistically significant. However, there were no significant differences between REQUIP XL 24-Hour compared to placebo in PDQ- 39 subscales of social support, cognition or bodily discomfort. Additionally, there was no significant difference between REQUIP XL 24-Hour and placebo on the Epworth Sleepiness Scale total score signifying no increase in daytime sleepiness.

In the EASE-PD Adjunct study, once daily use of REQUIP XL 24-Hour was generally well tolerated. The withdrawal rate due to adverse events was low and similar between the two groups (REQUIP XL 24-Hour 5 percent versus placebo 5 percent). The most common adverse events reported in patients taking REQUIP XL 24-Hour (n=202) versus placebo (n=191) were dyskinesia (13 percent versus 3 percent), nausea (11 percent versus 4 percent), dizziness (8 percent versus 3 percent), somnolence (7 percent versus 4 percent), hallucinations (6 percent versus 1 percent), and orthostatic hypotension (5 percent versus 2 percent).

A Progressively Disabling Disease

Parkinson's disease is a chronic, progressive and debilitating neurological condition that impairs the body's ability to move and balance. Researchers have determined that Parkinson's disease involves pathways in the brain responsible for motor control that are functioning improperly. Patients with Parkinson's disease experience a reduction in dopamine, a key chemical in the brain that communicates messages about movement, resulting in the symptoms of Parkinson's disease. These symptoms may include bradykinesia (slower-than- normal voluntary movements), rigidity (stiffness), tremor (involuntary shaking) and postural instability (trouble with balance).

More than one million people in the United States have Parkinson's disease, and it is estimated that nearly 60,000 new cases are diagnosed in the U.S. each year. Most people develop Parkinson's disease between the ages of 40 and
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
2. New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients
3. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
4. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
5. Alpharma Presents Positive Pharmacokinetic Study Results of Its Investigational Abuse-Deterrent, Extended-Release Opioid
6. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
7. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
8. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
9. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
10. Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
11. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds